Press Room

Duchesnay Inc. Announces $5 Million Investment in its Blainville Plant

Groupe pharmaceutique Boivin is proud to make this local investment in response to increasing global demand in Duchesnay’s products

BLAINVILLE, QC (CANADA), November 30, 2015 – Duchesnay Inc., the only pharmaceutical company in Canada dedicated to the health and quality of life of pregnant women and their unborn children, is undertaking a major expansion that will double its production space. The project is necessitated by rising demand for its flagship product Diclectin. A total of over 5 million dollars will be spent for work on the building and the purchase of latest-technology equipment. In addition, 15 new specialized jobs will also be added at the company’s Blainville facility. Construction is slated to begin in December 2015, for completion in 12 months.

“With a full backlog of orders, our priority is to maintain production during the construction period. Our plant is already producing Diclectin/Diclegis for Canada, the United States and Israel, Diclectin being sold under the name Dicelgis in the United States. We’re now also at work in developing new medications for pregnant women,” said Duchesnay Inc. Executive Vice-President Éric Gervais.

“This investment will double, even triple our production capacity to ensure the availability of our products. At a time when the big pharmaceutical companies are cutting back and conducting layoffs, Duchesnay is proud to be investing in the future,” added Mr. Gervais.


Duchesnay Inc. is a unique Québec pharmaceutical company, dedicated to the health and quality of life of expecting women and their unborn babies. To serve this purpose, the company works to advance maternal-fetal medicine in ways that will reduce the risk of birth defects, and to develop safe and effective pharmacological solutions for use during pregnancy and nursing. For more information, visit